UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 700

Sortiert nach

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom Study of 209 pregnant women

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.501-512

2013

Volltextzugriff (PDF)

Quality outcome measures project in IBD: a proof-of-concept benchmarking study in three Belgian IBD units

Acta gastro-enterologica belgica, 2023-10, Vol.86 (4), p.521-526

2023

Volltextzugriff (PDF)

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

Gut, 2007-09, Vol.56 (9), p.1226-1231

2007

Volltextzugriff (PDF)

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

Alimentary pharmacology & therapeutics, 2014-12, Vol.40 (11-12), p.1324-1332

2014

Volltextzugriff (PDF)

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

The New England journal of medicine, 2003-02, Vol.348 (7), p.601-608

2003

Volltextzugriff (PDF)

Child appraisals of injustice in the context of acute and chronic pain: An interpretative phenomenological analysis

European journal of pain, 2024-01, Vol.28 (1), p.54-69

2024

Volltextzugriff (PDF)

Updating the Taxonomy of Dermatophytes of the BCCM/IHEM Collection According to the New Standard: A Phylogenetic Approach

Mycopathologia (1975), 2020-02, Vol.185 (1), p.161-168

2020

Volltextzugriff (PDF)

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.1099-1105

2018

Volltextzugriff (PDF)

Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

Gastroenterology (New York, N.Y. 1943), 1999, Vol.116 (1), p.22-28

1999

Volltextzugriff (PDF)

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis

Journal of Crohn's and colitis, 2012-06, Vol.6 (5), p.557-562

2012

Volltextzugriff (PDF)

European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations

Gut, 2006-03, Vol.55 (suppl 1), p.i36-i58

2006

Volltextzugriff (PDF)

Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study

Gastroenterology (New York, N.Y. 1943), 2003-07, Vol.125 (1), p.32-39

2003

Volltextzugriff (PDF)

P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1429-i1431

2024

Volltextzugriff (PDF)

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

Gastroenterology (New York, N.Y. 1943), 1998-02, Vol.114 (2), p.262-267

1998

Volltextzugriff (PDF)

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

Gastroenterology (New York, N.Y. 1943), 1999-05, Vol.116 (5), p.1029-1034

1999

Volltextzugriff (PDF)

5-aminosalicylate is not protective from neoplasia in ulcerative colitis

The American journal of gastroenterology, 2013-06, Vol.108 (6), p.1015-1015

2013

Volltextzugriff (PDF)

An uncommon cause of coffee ground emesis : necrotizing enteritis with pneumatosis intestinalis

Acta gastro-enterologica belgica, 2018-01, Vol.81 (1), p.111

2018

Volltextzugriff (PDF)

Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study

Alimentary pharmacology & therapeutics, 2006-10, Vol.24 (7), p.1087-1097

2006

Volltextzugriff (PDF)

Collagenous and Lymphocytic Colitis: Systematic Review and Update of the Literature

Digestive diseases (Basel), 2009-01, Vol.27 (Suppl 1), p.137-145

2009

Volltextzugriff (PDF)

Ulcerative colitis treatment : an insight into daily clinical practice

Acta gastro-enterologica belgica, 2019-07, Vol.82 (3), p.365-372

2019

Volltextzugriff (PDF)

Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease

Alimentary pharmacology & therapeutics, 2012-04, Vol.35 (7), p.848-848

2012

Volltextzugriff (PDF)

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

Acta gastro-enterologica belgica, 2018-01, Vol.81 (1), p.49-53

2018

Volltextzugriff (PDF)

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients

Clinical biochemistry, 2011-09, Vol.44 (13), p.1062-1066

2011

Volltextzugriff (PDF)

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Acta gastro-enterologica belgica, 2018-01, Vol.81 (1), p.15-21

2018

Volltextzugriff (PDF)

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis

Gut, 1999-09, Vol.45 (3), p.375-381

1999

Volltextzugriff (PDF)

1 – 25 von 700

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(552)
Mit Volltextzugriff
(579)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(347)
Life Sciences & Biomedicine
(266)
Humans
(243)
Biological And Medical Sciences
(153)
Male
(137)
Medical Sciences
(132)
Female
(114)
Adult
(90)
Middle Aged
(73)
Physical Sciences
(73)
Gastroenterology & Hepatology
(66)
Aged
(62)
Chemistry
(57)
Animals
(55)
Exact Sciences And Technology
(49)
Physics
(46)
Radiology, Nuclear Medicine & Medical Imaging
(43)
Technology
(40)
Chemistry, Multidisciplinary
(32)
Condensed Matter: Structure, Mechanical And Thermal Properties
(32)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom Study of 209 pregnant women

Quality outcome measures project in IBD: a proof-of-concept benchmarking study in three Belgian IBD units

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Child appraisals of injustice in the context of acute and chronic pain: An interpretative phenomenological analysis

Updating the Taxonomy of Dermatophytes of the BCCM/IHEM Collection According to the New Standard: A Phylogenetic Approach

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis

European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations

Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study

P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

5-aminosalicylate is not protective from neoplasia in ulcerative colitis

An uncommon cause of coffee ground emesis : necrotizing enteritis with pneumatosis intestinalis

Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study

Collagenous and Lymphocytic Colitis: Systematic Review and Update of the Literature

Ulcerative colitis treatment : an insight into daily clinical practice

Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis

Suchergebnisse filtern